BETA2,086.00

Beta Drugs Limited

· Unclassified
AnnualQuarterly₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹2,115 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q4 FY25
31/03/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations182.1203.687.394.0125.5
Other Income4.96.02.32.91.6
Total Income187.0209.689.696.9127.1
Expenses
+ Cost of Materials Consumed88.0104.532.536.850.2
+ Changes in Inventories-1.7-5.53.5-0.74.3
+ Employee Benefit Expense17.719.216.818.720.4
+ Finance Costs5.26.94.43.92.6
+ Depreciation & Amortisation6.88.04.44.84.3
+ Other Expenses42.344.317.421.523.3
Total Expenses158.2177.579.185.0105.1
EBITDA35.841.017.017.727.4
EBIT29.033.012.612.923.0
Profit
PBT before Exceptional Items24.232.110.511.822.0
+ Exceptional Items-4.60.00.00.00.0
Pretax Income24.232.110.511.822.0
+ Current Tax6.48.52.13.05.8
+ Deferred Tax-0.2-0.4-0.2-0.2-0.3
Tax Expense6.28.22.02.85.6
Net Income18.023.98.59.016.5
+ Net Income — Continuing Ops8.59.016.5
+ Other Comprehensive Income0.00.20.0
Total Comprehensive Income8.59.216.5
Minority Interest0.0-0.7
Per Share
Basic EPS17.8147.388.408.9314.78
Diluted EPS17.8147.388.408.9314.78
Profit Build-up — Alternate / Pre-Ind-AS Tags
PBT before Exceptional & Extraordinary Items28.832.1
+ Adjustments to Profit / (Loss)14.9
Profit for the Period before Minority Interest18.023.9
Continuing & Discontinued Operations
Profit from Continuing Operations18.023.9
Other Comprehensive Income — detail
+ Other Comprehensive Income0.00.2
+ Items NOT to be Reclassified to P&L0.2
Per Share — as-filed variants
Basic EPS — Continuing Operations8.408.9314.78
Diluted EPS — Continuing Operations8.408.9314.78
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit95.8104.651.257.971.0
Gross Margin %52.6251.3558.7061.5956.58
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)24.232.110.511.822.0
− Exceptional Items (reconciliation)-4.60.00.00.00.0
Net Income Adj (tax-effected)18.023.98.59.016.5
EPS Adj17.8147.388.408.9314.78
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.00
Filed Debt Equity0.010.01
Filed Dscr0.050.09
Filed Iscr0.060.11
Paid Up Equity Capital10.110.110.110.111.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.